Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Medical Genetics
Published in: BMC Medical Genetics 1/2012

Open Access 01-12-2012 | Research article

Peripheral PDLIM5 expression in bipolar disorder and the effect of olanzapine administration

Authors: Mohd Aizat Zain, Suffee Nusrat Jahan, Gavin P Reynolds, Nor Zuraida Zainal, Sharmilla Kanagasundram, Zahurin Mohamed

Published in: BMC Medical Genetics | Issue 1/2012

Login to get access

Abstract

Background

One of the genes suggested to play an important role in the pathophysiology of bipolar disorder (BPD) is PDLIM5, which encodes LIM domain protein. Our main objective was to examine the effect of olanzapine treatment on PDLIM5 mRNA expression in the peripheral blood leukocytes of BPD patients.

Methods

We measured the expression of PDLIM5 mRNA from 16 patients with BPD Type I after 0, 4, and 8 weeks of treatment with olanzapine using quantitative real-time PCR. The Young Mania Rating Scale was used to evaluate the severity of manic symptoms in BPD patients. We also compared PDLIM5 mRNA expression in treatment-naïve BPD patients with that in healthy control subjects.

Results

No significant difference was found in PDLIM5 mRNA expression between patients before olanzapine treatment and following 4 and 8 weeks of treatment (p>0.05). Although we observed a significant reduction in the severity of manic symptoms in all BPD patients (p<0.05), the effectiveness of the medication did not significantly correlate with the expression of PDLIM5 mRNA (p>0.05). Interestingly, PDLIM5 mRNA expression differed significantly between treatment-naïve BPD patients and healthy control subjects (p=0.002).

Conclusion

PDLIM5 mRNA expression did not appear to be a reflection of the efficacy of olanzapine in reducing the manic symptoms of BPD. The significant difference in expression of PDLIM5 mRNA in the peripheral blood leukocytes of treatment-naïve BPD patients versus that of healthy control subjects, however, suggests that it may be a good biological marker for BPD.
Appendix
Available only for authorised users
Literature
1.
van Loo KM, Martens GJ: Genetic and environmental factors in complex neurodevelopmental disorders. Curr Genomics. 2007, 8 (7): 429-444. 10.2174/138920207783591717.CrossRefPubMedPubMedCentral
2.
Kato T: Molecular genetics of bipolar disorder and depression. Psychiatry Clin Neurosci. 2007, 61 (1): 3-19. 10.1111/j.1440-1819.2007.01604.x.CrossRefPubMed
3.
Maeno-Hikichi Y, Chang S, Matsumura K, Lai M, Lin H, Nakagawa N, Kuroda S, Zhang JF: A PKC epsilon-ENH-channel complex specifically modulates N-type Ca2+ channels. Nat Neurosci. 2003, 6 (5): 468-475.PubMed
4.
Kuroda S, Tokunaga C, Kiyohara Y, Higuchi O, Konishi H, Mizuno K, Gill GN, Kikkawa U: Protein-protein interaction of zinc finger LIM domains with protein kinase C. J Biol Chem. 1996, 271 (49): 31029-31032. 10.1074/jbc.271.49.31029.CrossRefPubMed
5.
6.
Kato T, Iwayama Y, Kakiuchi C, Iwamoto K, Yamada K, Minabe Y, Nakamura K, Mori N, Fujii K, Nanko S, et al: Gene expression and association analyses of LIM (PDLIM5) in bipolar disorder and schizophrenia. Mol Psychiatry. 2005, 10 (11): 1045-1055. 10.1038/sj.mp.4001719.CrossRefPubMed
7.
Zhao T, Liu Y, Wang P, Li S, Zhou D, Zhang D, Chen Z, Wang T, Xu H, Feng G, et al: Positive association between the PDLIM5 gene and bipolar disorder in the Chinese Han population. J Psychiatry Neurosci. 2009, 34 (3): 199-204.PubMedPubMedCentral
8.
Horiuchi Y, Arai M, Niizato K, Iritani S, Noguchi E, Ohtsuki T, Koga M, Kato T, Itokawa M, Arinami T: A polymorphism in the PDLIM5 gene associated with gene expression and schizophrenia. Biol Psychiatry. 2006, 59 (5): 434-439. 10.1016/j.biopsych.2005.07.041.CrossRefPubMed
9.
Liu Z, Liu W, Xiao Z, Wang G, Yin S, Zhu F, Wang H, Cheng J, Wang X, He X, et al: A major single nucleotide polymorphism of the PDLIM5 gene associated with recurrent major depressive disorder. J Psychiatry Neurosci. 2008, 33 (1): 43-46.PubMedPubMedCentral
10.
Squassina A, Manchia M, Manconi F, Piccardi M, Ardau R, Chillotti C, Severino G, Del Zompo M: A case–control association study of the PDLIM5 gene and bipolar disorder in a Sardinian sample. Psychiatr Genet. 2008, 18 (3): 128-132. 10.1097/YPG.0b013e3282fb003d.CrossRefPubMed
11.
Shi J, Badner JA, Liu C: PDLIM5 and susceptibility to bipolar disorder: a family-based association study and meta-analysis. Psychiatr Genet. 2008, 18 (3): 116-121. 10.1097/YPG.0b013e3282fa184b.CrossRefPubMedPubMedCentral
12.
Numata S, Ueno S, Iga J, Yamauchi K, Hongwei S, Hashimoto R, Takeda M, Kunugi H, Itakura M, Ohmori T: Gene expression in the peripheral leukocytes and association analysis of PDLIM5 gene in schizophrenia. Neurosci Lett. 2007, 415 (1): 28-33. 10.1016/j.neulet.2007.01.018.CrossRefPubMed
13.
Iga J, Ueno S, Yamauchi K, Numata S, Motoki I, Tayoshi S, Kinouchi S, Ohta K, Song H, Morita K, et al: Gene expression and association analysis of LIM (PDLIM5) in major depression. Neurosci Lett. 2006, 400 (3): 203-207. 10.1016/j.neulet.2006.02.044.CrossRefPubMed
14.
Iwamoto K, Kakiuchi C, Bundo M, Ikeda K, Kato T: Molecular characterization of bipolar disorder by comparing gene expression profiles of postmortem brains of major mental disorders. Mol Psychiatry. 2004, 9 (4): 406-416. 10.1038/sj.mp.4001437.CrossRefPubMed
15.
Iwamoto K, Bundo M, Washizuka S, Kakiuchi C, Kato T: Expression of HSPF1 and LIM in the lymphoblastoid cells derived from patients with bipolar disorder and schizophrenia. J Hum Genet. 2004, 49 (5): 227-231. 10.1007/s10038-004-0136-5.CrossRefPubMed
16.
Hahn CG, Friedman E: Abnormalities in protein kinase C signaling and the pathophysiology of bipolar disorder. Bipolar Disord. 1999, 1 (2): 81-86. 10.1034/j.1399-5618.1999.010204.x.CrossRefPubMed
17.
Pandey GN, Ren X, Dwivedi Y, Pavuluri MN: Decreased protein kinase C (PKC) in platelets of pediatric bipolar patients: effect of treatment with mood stabilizing drugs. J Psychiatr Res. 2008, 42 (2): 106-116. 10.1016/j.jpsychires.2006.11.004.CrossRefPubMed
18.
Maturana AD, Nakagawa N, Yoshimoto N, Tatematsu K, Hoshijima M, Tanizawa K, Kuroda S: LIM domains regulate protein kinase C activity: a novel molecular function. Cell Signal. 2011, 23 (5): 928-934. 10.1016/j.cellsig.2011.01.021.CrossRefPubMed
19.
Herrick S, Evers DM, Lee JY, Udagawa N, Pak DT: Postsynaptic PDLIM5/Enigma Homolog binds SPAR and causes dendritic spine shrinkage. Mol Cell Neurosci. 2010, 43 (2): 188-200. 10.1016/j.mcn.2009.10.009.CrossRefPubMed
20.
Squassina A, Congiu D, Manconi F, Manchia M, Chillotti C, Lampus S, Severino G, Zompo MD: The PDLIM5 gene and lithium prophylaxis: an association and gene expression analysis in Sardinian patients with bipolar disorder. Pharmacol Res. 2008, 57 (5): 369-373. 10.1016/j.phrs.2008.03.011.CrossRefPubMed
21.
Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, Purgato M, Spineli LM, Goodwin GM, Geddes JR: Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet. 2011, 378 (9799): 1306-1315. 10.1016/S0140-6736(11)60873-8.CrossRefPubMed
22.
Moreno RA, Moreno DH, Soares MB, Ratzke R: [Anticonvulsants and antipsychotics in the treatment of bipolar disorder]. Rev Bras Psiquiatr. 2004, 26 (Suppl 3): 37-43.CrossRefPubMed
23.
Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, Sanger T, Risser R, Zhang F, Toma V, et al: Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry. 2000, 57 (9): 841-849. 10.1001/archpsyc.57.9.841.CrossRefPubMed
24.
Tohen M, Chengappa KN, Suppes T, Zarate CA, Calabrese JR, Bowden CL, Sachs GS, Kupfer DJ, Baker RW, Risser RC, et al: Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry. 2002, 59 (1): 62-69. 10.1001/archpsyc.59.1.62.CrossRefPubMed
25.
Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L: [Antipsychotics in bipolar disorders]. Encephale. 2004, 30 (5): 417-424. 10.1016/S0013-7006(04)95456-5.CrossRefPubMed
26.
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC: The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998, 59 (Suppl 20): 22-33. quiz 34–57PubMed
27.
Shi YY, He L: SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 2005, 15 (2): 97-98. 10.1038/sj.cr.7290272.CrossRefPubMed
28.
29.
Wilson JF, Weale ME, Smith AC, Gratrix F, Fletcher B, Thomas MG, Bradman N, Goldstein DB: Population genetic structure of variable drug response. Nat Genet. 2001, 29 (3): 265-269. 10.1038/ng761.CrossRefPubMed
30.
Reynolds GP: Receptor mechanisms of antipsychotic drug action in bipolar disorder – focus on asenapine. Therapeutic Advances in Psychopharmacology. 2011, 1 (6): 197-204. 10.1177/2045125311430112.CrossRefPubMedPubMedCentral
31.
Schloesser RJ, Huang J, Klein PS, Manji HK: Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology. 2008, 33 (1): 110-133. 10.1038/sj.npp.1301575.CrossRefPubMed
32.
Singh RK, Shi J, Zemaitaitis BW, Muma NA: Olanzapine increases RGS7 protein expression via stimulation of the Janus tyrosine kinase-signal transducer and activator of transcription signaling cascade. J Pharmacol Exp Ther. 2007, 322 (1): 133-140. 10.1124/jpet.107.120386.CrossRefPubMed
33.
Tohen M, Baker RW, Altshuler LL, Zarate CA, Suppes T, Ketter TA, Milton DR, Risser R, Gilmore JA, Breier A, et al: Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry. 2002, 159 (6): 1011-1017. 10.1176/appi.ajp.159.6.1011.CrossRefPubMed
34.
Metadata
Title
Peripheral PDLIM5 expression in bipolar disorder and the effect of olanzapine administration
Authors
Mohd Aizat Zain
Suffee Nusrat Jahan
Gavin P Reynolds
Nor Zuraida Zainal
Sharmilla Kanagasundram
Zahurin Mohamed
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Medical Genetics / Issue 1/2012
Electronic ISSN: 1471-2350
DOI
https://doi.org/10.1186/1471-2350-13-91

Other articles of this Issue 1/2012

BMC Medical Genetics 1/2012 Go to the issue

Research article

Association of ALOX5APgene single nucleotide polymorphisms and cerebral infarction in the Han population of northern China

Research article

MUC2polymorphisms are associated with endometriosis development and infertility: a case-control study

Research article

Prediction of lung cancer risk in a Chinese population using a multifactorial genetic model

Research article

Functional effects of the TMEM43 Ser358Leu mutation in the pathogenesis of arrhythmogenic right ventricular cardiomyopathy

Research article

Association between XRCC1polymorphism 399 G->A and glioma among Caucasians: a systematic review and meta-analysis

Research article

Genetic variations in APPL2 are associated with overweight and obesity in a Chinese population with normal glucose tolerance